These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 30936353)

  • 1. Can typical and atypical antipsychotics show differential effectiveness in treating paranoia and hallucinations in schizophrenia?
    Osimo EF; Goujon MJ; Perez J; Murray GK
    BMJ Case Rep; 2019 Mar; 12(3):. PubMed ID: 30936353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frontal D2/3 Receptor Availability in Schizophrenia Patients Before and After Their First Antipsychotic Treatment: Relation to Cognitive Functions and Psychopathology.
    Nørbak-Emig H; Ebdrup BH; Fagerlund B; Svarer C; Rasmussen H; Friberg L; Allerup PN; Rostrup E; Pinborg LH; Glenthøj BY
    Int J Neuropsychopharmacol; 2016 May; 19(5):. PubMed ID: 26819282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential Effectiveness of Atypical Antipsychotics on Hallucinations: A Pragmatic Randomized Controlled Trial.
    Sinkeviciute I; Hugdahl K; Bartz-Johannessen C; Kroken RA; Løberg EM; Kjelby E; Rettenbacher MA; Joa I; Reitan SK; Alisauskiene R; Fathian F; Johnsen E
    J Clin Psychopharmacol; 2021 Jul-Aug 01; 41(4):389-396. PubMed ID: 33938520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dopamine antagonist antipsychotics in diverted forensic populations.
    Cummings MA; Proctor GJ; Arias AW
    CNS Spectr; 2020 Apr; 25(2):128-135. PubMed ID: 31060635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Limbic circuits and monoamine receptors: dissecting the effects of antipsychotics from disease processes.
    Joyce JN; Goldsmith SG; Gurevich EV
    J Psychiatr Res; 1997; 31(2):197-217. PubMed ID: 9278186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atypical antipsychotic agents: a critical review.
    Worrel JA; Marken PA; Beckman SE; Ruehter VL
    Am J Health Syst Pharm; 2000 Feb; 57(3):238-55. PubMed ID: 10674777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Olanzapine: a serotonin-dopamine-receptor antagonist for antipsychotic therapy.
    Bever KA; Perry PJ
    Am J Health Syst Pharm; 1998 May; 55(10):1003-16. PubMed ID: 9606451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circadian patterns of hallucinatory experiences in patients with schizophrenia: Potentials for chrono-pharmacology.
    Koizumi T; Suzuki T; Pillai NS; Bies RR; Takeuchi H; Yoshimura K; Mimura M; Uchida H
    J Psychiatr Res; 2019 Oct; 117():1-6. PubMed ID: 31254838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does early improvement predict response to the fast-dissociating D₂ receptor antagonist JNJ-37822681 in patients with acute schizophrenia?
    Anghelescu IG; Janssens L; Kent J; de Boer P; Tritsmans L; Daly EJ; van Nueten L; Schmidt ME
    Eur Neuropsychopharmacol; 2013 Sep; 23(9):1043-50. PubMed ID: 22995972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amisulpride a selective dopamine antagonist and atypical antipsychotic: results of a meta-analysis of randomized controlled trials.
    Leucht S
    Int J Neuropsychopharmacol; 2004 Mar; 7 Suppl 1():S15-20. PubMed ID: 14972080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amisulpride, aripiprazole, and olanzapine in patients with schizophrenia-spectrum disorders (BeSt InTro): a pragmatic, rater-blind, semi-randomised trial.
    Johnsen E; Kroken RA; Løberg EM; Rettenbacher M; Joa I; Larsen TK; Reitan SK; Walla B; Alisauskiene R; Anda LG; Bartz-Johannessen C; Berle JØ; Bjarke J; Fathian F; Hugdahl K; Kjelby E; Sinkeviciute I; Skrede S; Stabell L; Steen VM; Fleischhacker WW
    Lancet Psychiatry; 2020 Nov; 7(11):945-954. PubMed ID: 33069317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intramuscular olanzapine versus short-acting typical intramuscular antipsychotics: comparison of real-life effectiveness in the treatment of agitation.
    Castle DJ; Udristoiu T; Kim CY; Sarosi A; Pidrman V; Omar AN; Rosales JI; Melamed Y; Isik T; Karagianis J; Treuer T
    World J Biol Psychiatry; 2009; 10(1):43-53. PubMed ID: 19137460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dopamine D₃ receptor antagonism--still a therapeutic option for the treatment of schizophrenia.
    Gross G; Wicke K; Drescher KU
    Naunyn Schmiedebergs Arch Pharmacol; 2013 Feb; 386(2):155-66. PubMed ID: 23128852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic-pharmacodynamic modelling of antipsychotic drugs in patients with schizophrenia: part II: the use of subscales of the PANSS score.
    Pilla Reddy V; Kozielska M; Suleiman AA; Johnson M; Vermeulen A; Liu J; de Greef R; Groothuis GM; Danhof M; Proost JH
    Schizophr Res; 2013 May; 146(1-3):153-61. PubMed ID: 23473811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia.
    Lindenmayer JP; Khan A; Iskander A; Abad MT; Parker B
    J Clin Psychiatry; 2007 Mar; 68(3):368-79. PubMed ID: 17388705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Some dopaminergic genes polymorphisms are not associated with response to antipsychotic drugs in schizophrenic patients.
    Tybura P; Samochowiec A; Beszlej A; Grzywacz A; Mak M; Frydecka D; Bieńkowski P; Mierzejewski P; Potemkowski A; Samochowiec J
    Pharmacol Rep; 2012; 64(3):528-35. PubMed ID: 22814006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A double-blind, randomized, placebo-controlled study with JNJ-37822681, a novel, highly selective, fast dissociating D₂ receptor antagonist in the treatment of acute exacerbation of schizophrenia.
    Schmidt ME; Kent JM; Daly E; Janssens L; Van Osselaer N; Hüsken G; Anghelescu IG; Van Nueten L
    Eur Neuropsychopharmacol; 2012 Oct; 22(10):721-33. PubMed ID: 22464973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics.
    Tauscher J; Hussain T; Agid O; Verhoeff NP; Wilson AA; Houle S; Remington G; Zipursky RB; Kapur S
    Am J Psychiatry; 2004 Sep; 161(9):1620-5. PubMed ID: 15337652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The 5-HT2 receptor profiles of antipsychotics in the pathogenesis of obsessive-compulsive symptoms in schizophrenia.
    Kim SW; Shin IS; Kim JM; Youn T; Yang SJ; Hwang MY; Yoon JS
    Clin Neuropharmacol; 2009; 32(4):224-6. PubMed ID: 19644229
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Zuclopenthixol acetate in the treatment of acute schizophrenia and similar serious mental illnesses.
    Fenton M; Coutinho ES; Campbell C
    Cochrane Database Syst Rev; 2001; (3):CD000525. PubMed ID: 11686965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.